구분 |
보고서(영문) |
제약/바이오/ 임상시험 (3건) |
Bio/Pharmaceutical Outsourcing Report, August 2024 |
Migraine Market Expected to Reach $16.4 Billion Across 7MM by 2033 |
Emerging Microbiome Market—Unlocking New Frontiers |
컨퍼런스/ 심포지엄/ 학회/기타 (17건) |
ESC 2024: Obicetrapib - A Promising Breakthrough for Dyslipidemia Treatment |
ESC 2024: SELECT Trial Provides Promising Results for the Treatment of Obesity-Related HFpEF with Semaglutide 2.4mg |
ESC 2024: Additional Analysis of FLOW Trial Highlights That CKD Patients Could Positively Benefit From Ozempic |
ESC 2024: Retatrutide Improves Lipid and Cardiovascular Risk Profile in Phase II Trial |
ESC 2024: Study Highlights Novartis’ Potential to Differentiate in HF Space |
ESC 2024: Sacubitril/Valsartan Continues to Impress in HF |
ESC 2024: FINEARTS-HF Trial Sheds Positive Light on Kerendia for HFmrEF/HFpEF |
ESC 2024: Results From CATHEDRAL-HF Trial Has the Potential to Reduce Polypharmacy |
ESC 2024: GLP-1RAs Lower Cardiovascular Risk in Meta-Analysis of 32,884 Patients |
EASD 2024: Survodutide Shows Promise in Overweight, Obesity, and MASH |
EASD 2024: Novel Insights into Maternal Protection in Type 1 Diabetes |
EASD 2024: Bayer’s Kerendia Continues to Impress with Pooled Analysis |
EASD 2024: Cardiovascular and Inflammatory Markers Decrease after Treatment with Oral GLP-1R Agonist Orforglipron |
EASD 2024: Mazdutide Improves Cardiometabolic Function in Patients with Obesity or Overweight |
EASD 2024: New Developments in Presymptomatic Type 1 Diabetes Screening |
EASD 2024: Are Tetra-Agonists the Future of Metabolic Diseases Treatment? |
EASD 2024: A COMBINEd Approach for Better Diabetes Management |
질환별 (5건) |
NICE Approves New Osteoporosis Treatment for High-Risk Patients in the UK |
Sickle Cell in September: Spreading Awareness and Supporting Solutions |
Rising ADHD Diagnoses in 7MM Linked to Standardized Screening Tools and Guidelines |
Uterine Leiomyoma: Competitive Landscape |
Dysmenorrhea: Competitive Landscape |